Description
The abstract mentions therapeutic approaches targeting both TDP-43 function restoration and aggregation prevention, but doesn’t clarify which strategy is more effective or how to optimize target selection. This gap hampers rational therapeutic development for TDP-43 proteinopathies.
Gap type: open_question Source paper: The mechanisms underlying TDP-43-associated neurodegeneration in Alzheimer’s disease and related dementias. (None, None, PMID:40562864)
Resolution criteria
[“Comparative efficacy study of TDP-43 function restoration (antisense oligonucleotides targeting splicing) vs aggregation prevention (small molecule disaggregases) in iPSC-derived neurons from ALS/FTLD patients”, “Survival assay (ATP content and LDH release) at 21 days post-treatment identifies which strategy achieves >=50% neuroprotection”, “Pharmacokinetic analysis of blood-brain barrier penetration for aggregation inhibitors confirms brain exposure at effective concentrations”, “In vivo validation in TDP-43 transgenic mice shows functional restoration vs aggregation reduction with distinct behavioral readouts”]
Evidence summary
Resolved by hypothesis h-ccc05373: p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphorylation-Methylation Balance. Score: 0.879. Supporting PMIDs: 39817908, NCT05869669, 39817908, NCT05869669, 39817908.